Oruka Therapeutics, Inc. — Director's Dealing 2016

Feb 16, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2016-02-11

Reporting Person: MITCHELL DANIEL J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-11	Stock Option (right to buy)	$3.44	A	8000	Acquired	2026-02-10	Common Stock (8000)	Direct

Footnotes

F1: Grant to the Reporting Person of a stock option under the 2013 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2016. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.